Acute megakaryoblastic leukemia (AMKL) is a heterogeneous disease with a relatively poorly understood pathogenesis. In this issue of Cancer Cell, Thirant and colleagues systematically examine unique transcriptional and functional effects of ETO2-GLIS2, an oncogenic fusion protein frequently encountered in AMKL, and elucidate a therapeutic vulnerability in this poor-prognosis leukemia.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Mar 13 2017|
ASJC Scopus subject areas
- Cell Biology
- Cancer Research